Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    San Diego, CA

    Search
    San Diego, CA
    Show Map
    Map View
    San Diego, CA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      211 Clinical Paid Trials near San Diego, CA

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      CVXGA Vaccine for Coronavirus

      La Mesa, California
      The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 434 healthy participants.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Acute Illness, Positive COVID-19, Autoimmune, Others
      Must Not Be Taking:Intranasal Medications, Immunosuppressants

      432 Participants Needed

      A2B395 CAR T-Cell Therapy for Colorectal Cancer

      La Jolla, California
      The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the recommended dose of A2B395 that is safe for patients * Phase 2: Does the recommended dose of A2B395 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: * Enrollment in BASECAMP-1 (NCT04981119) * Preconditioning lymphodepletion (PCLD) regimen * A2B395 Tmod CAR T cells at the assigned dose
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Prior Transplants, Recent Cancer Therapy, Cardiac Disease, Others

      240 Participants Needed

      Ileostomy Infusion for Ileostomy

      La Jolla, California
      This research study is being conducted to study the effect of infusing your contents from your ostomy bag back into your intestine to re-train them prior to the ostomy takedown operation, which is a surgery to reverse your ostomy to put your intestine back together. Because your intestine past the ostomy hasn't seen any intestinal content for several weeks to months before the takedown operation, it is no longer used to handling the daily work of processing intestinal content and will take time to recover its normal function after surgery. We hope to speed up this process by training them before your planned surgery.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Unable To Consent, Stoma Infusion

      20 Participants Needed

      RAS(ON) Inhibitors for Gastrointestinal Cancer

      La Jolla, California
      The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Tumors, Impaired GI Function, Others

      1130 Participants Needed

      Phage Therapy for Recurrent UTIs

      La Jolla, California
      This proposal will take an important first step in the study of phage therapy for treatment of recurrent urinary tract infection (rUTI) in female kidney transplant recipients (KTR); a common condition that is associated with increasing multidrug resistance, sickness, loss of kidney function and death. The investigators will conduct a randomized phase I/II pilot clinical trial of targeted phage therapy versus placebo in asymptomatic female KTR with a history of rUTI due to Escherichia coli to assess safety, tolerability, and feasibility of this approach, possible efficacy, and changes in the gut and urinary microbiome during the 180 days of the study. This highly innovative and impactful proposal will provide proof of concept data and also inform the design of a subsequent larger phase III clinical trial of phage therapy for rUTI treatment in KTR and will have broad downstream effects within the fields of infectious diseases and transplantation.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Urinary Hardware, Multiple Transplants, Pregnancy, Others

      32 Participants Needed

      Cabotegravir + Rilpivirine for HIV During Pregnancy

      La Jolla, California
      This is a Phase I/II, multicenter, open-label, non-randomized study with four groups to characterize the pharmacokinetics and safety of Cabotegravir (CAB) and Rilpivirine (RPV) long-acting injectable (LA) during pregnancy and postpartum among people with HIV-1 viral suppression and their infants.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1, 2
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Hepatitis B, Hepatitis C, Tuberculosis, Others
      Must Be Taking:Antiretrovirals

      45 Participants Needed

      Iadademstat + Atezolizumab/Durvalumab for Small Cell Lung Cancer

      La Jolla, California
      This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage) who initially received standard of care chemotherapy and immunotherapy. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding iadademstat to either atezolizumab or durvalumab may be able to stabilize cancer for longer than atezolizumab or durvalumab alone in treating patients with extensive stage small cell lung cancer.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Organ Transplant, Others
      Must Be Taking:Platinum Etoposide Chemotherapy

      45 Participants Needed

      FMC-376 for Solid Tumors

      La Jolla, California
      The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Leptomeningeal Disease, Carcinomatous Meningitis, Others

      403 Participants Needed

      A2B694 CAR T-Cells for Solid Cancers

      La Jolla, California
      This trial tests a new immune cell therapy for adults with difficult-to-treat solid tumors. The therapy modifies the patient's own immune cells to target and kill cancer cells while protecting healthy cells. The study aims to find a safe dose and see how well it works.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Prior Transplants, Cardiac Disease, Lung Disease, Others

      230 Participants Needed

      VCAR33 for Leukemia

      La Jolla, California
      This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Multiple AlloHCT, Active GVHD, CNS Disease, Others
      Must Not Be Taking:Immunosuppressants

      38 Participants Needed

      Immunotherapy + Prednisone + Sirolimus for Skin Cancer

      La Jolla, California
      This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started to other places in the body (metastatic) in kidney transplant recipients. Immunotherapy with nivolumab and ipilimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Sirolimus and prednisone are immunosuppressants that are given to keep the body from rejecting the transplanted kidney. Giving nivolumab and ipilimumab in combination with sirolimus and prednisone may kill more cancer cells, while also keeping the transplanted kidney healthy, in patients with unresectable or metastatic cutaneous cancer who have received a kidney transplant.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Liver Transplant, Active Infection, Others
      Must Be Taking:Sirolimus, Prednisone

      16 Participants Needed

      TAC01-CLDN18.2 Engineered T-cells for Cancer

      San Diego, California
      TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. TAC directs T-cells to the targeted antigen (CLDN 18.2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicenter Phase ½ study that aims to establish safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-CLDN18.2.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Pathology, Active Autoimmune, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids

      113 Participants Needed

      TN-201 for Hypertrophic Cardiomyopathy

      La Jolla, California
      This trial tests a new drug, TN-201, in adults with a specific genetic heart condition. It aims to see if the drug is safe and how it affects their health over several years.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:High AAV9 Antibody Titer

      30 Participants Needed

      A2B530 CAR T Therapy for Solid Cancers

      La Jolla, California
      This trial tests A2B530, a treatment using modified immune cells from the patient, in adults with hard-to-treat cancers like colorectal, pancreatic, and lung cancer. The treatment aims to target and kill cancer cells while protecting healthy cells.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Local Therapy, Stem Cell Transplant, Organ Transplant, Others

      160 Participants Needed

      Sotagliflozin + Volagidemab for Type 1 Diabetes

      La Jolla, California
      This is a single site, double-blind, placebo-controlled, crossover trial to quantify the effects of combination adjunctive therapy on glycemic control, ketogenesis during insulinopenia, insulin resistance, and diabetes burden and quality of life.
      Stay on current meds

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Pancreatitis, Liver Disease, Anemia, Others
      Must Be Taking:Insulin

      24 Participants Needed

      Gene-Modified T Cell Therapy for Glioblastoma

      La Jolla, California
      This multicenter, Phase 1b/2 study is being conducted to determine if the experimental cell therapy is safe, tolerable and can delay the return of cancer in patients with a newly diagnosed or recurrent glioblastoma multiforme (GBM) in combination with standard chemotherapy treatment temozolomide (TMZ). If there is a 25% or greater improvement in survival in this study then the therapy should be studied further.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Concurrent Malignancy, Uncontrolled Illness, Others
      Must Be Taking:Temozolomide

      4 Participants Needed

      RSV Vaccine for Respiratory Syncytial Virus

      La Mesa, California
      This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 10\^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered in infants (8-24 months of age) and children (18-59 months of age) who may or may not have had prior respiratory syncytial virus (RSV) infection.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:6 - 5

      Key Eligibility Criteria

      Disqualifiers:Chronic Disease, Pulmonary Abnormality, Neurological Conditions, Others
      Must Not Be Taking:Immunosuppressants, Systemic Steroids, Intranasal Meds, Others

      137 Participants Needed

      PRO1184 for Cancer

      San Diego, California
      This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Interstitial Lung Disease, Others
      Must Be Taking:Platinum-based Chemotherapy

      569 Participants Needed

      DYNE-251 for Duchenne Muscular Dystrophy

      La Jolla, California
      This trial tests DYNE-251, an IV drug, in people with Duchenne muscular dystrophy who can benefit from exon 51 skipping. The drug aims to help their muscles by increasing the dystrophin protein. It works by skipping a faulty part of their gene to produce more of this important protein. Eteplirsen (Exondys 51) was the first drug approved for exon 51 skipping in Duchenne muscular dystrophy.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:4 - 16
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Congestive Heart Failure, Major Surgery, Others
      Must Be Taking:Glucocorticoids

      86 Participants Needed

      Acetazolamide for Type 1 Diabetes

      La Jolla, California
      This is a dose finding trial where participants will receive escalating doses of acetazolamide, each for a 2-week dosing period followed by a 2-week washout period. The three doses examined will be open-label 62.5mg twice daily, 125mg twice daily, and 250mg twice daily of acetazolamide. A baseline Iohexol GFR (glomerular filtration rate) measurement will be performed prior to the first administration of each acetazolamide dose and then again following each dosing period. Including a screening visit and a follow-up visit, there will be a total of 8 study visits over approximately 16 weeks.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Liver Disease, Pregnancy, Others
      Must Be Taking:Insulin

      12 Participants Needed

      Why Other Patients Applied

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31
      Match to a Trial

      Selinexor + Temozolomide for Recurrent Glioblastoma

      La Jolla, California
      This trial tests selinexor with temozolomide for patients whose brain cancer has returned. Selinexor blocks a protein that helps cancer cells grow, and temozolomide damages their DNA to kill them or stop their growth. Temozolomide is a DNA methylating drug currently used as a first-line treatment in glioblastoma therapy.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Illness, Pregnant, Severe COVID-19, Others
      Must Not Be Taking:Bevacizumab, Dacarbazine

      97 Participants Needed

      OCU400 for Retinitis Pigmentosa

      La Jolla, California
      This trial tests OCU400, an eye injection, in patients with specific genetic mutations causing RP and LCA. The treatment aims to correct faulty genes to prevent vision loss.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:6+

      Key Eligibility Criteria

      Disqualifiers:Gene Therapy, Intraocular Surgery, Infections, Others

      22 Participants Needed

      Gene Therapy for Hereditary Angioedema

      San Diego, California
      This trial tests BMN 331, a gene therapy given through an IV, for people with hereditary angioedema (HAE) who lack a specific protein. The therapy uses a virus to deliver a healthy gene to liver cells, enabling them to produce the missing protein. The study aims to see if this treatment is safe and effective over several years. BMN 331 is a gene therapy that uses a virus to deliver a healthy gene to liver cells, a method that has shown promise in treating various genetic disorders.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Infection, Malignancy, Liver Disease, Others
      Must Be Taking:HAE Medications

      44 Participants Needed

      STMC-103H for Allergies

      San Diego, California
      This trial is testing a new treatment called STMC-103H to see if it can help prevent allergic diseases in young children. The study focuses on babies and infants who are at risk of developing allergies. The treatment aims to improve their immune system's response to allergens, potentially reducing conditions like atopic dermatitis.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:0 - 14

      Key Eligibility Criteria

      Disqualifiers:Congenital Abnormalities, Immune Deficiency, Others
      Must Not Be Taking:Systemic Antibiotics

      264 Participants Needed

      Stem Cell Transplant + Mylotarg for Acute Myeloid Leukemia

      La Jolla, California
      This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Prior Stem Cell Transplant, CNS Leukemia, Gilbert's Syndrome, Others
      Must Not Be Taking:Mylotarg

      67 Participants Needed

      EG-70 for Bladder Cancer

      San Diego, California
      This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or inadequately treated.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Recent Malignancy, Renal Failure, Metastatic Disease, Others
      Must Not Be Taking:Chemotherapy, Pembrolizumab

      350 Participants Needed

      SRD-001 for Heart Failure

      San Diego, California
      This trial uses a harmless virus to deliver a gene that helps heart cells produce a beneficial protein. It targets patients with severe heart failure who don't respond well to other treatments. The treatment works by improving calcium handling in heart cells, which enhances heart function and blood flow. Gene therapy has recently emerged as a powerful tool offering the promise of a new paradigm for alleviating heart failure.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Cardiomyopathy, Myocarditis, Cancer, Others
      Must Be Taking:Guideline-directed Therapy

      57 Participants Needed

      CFI-402411 + Pembrolizumab for Solid Cancer

      La Jolla, California
      This trial is testing a new pill called CFI-402411, alone and with another drug, pembrolizumab, in patients with advanced cancers that haven't responded to other treatments. The new pill works by blocking a protein that may help the immune system attack the cancer. Combining it with pembrolizumab could make this effect even stronger.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Heart Failure, CNS Metastasis, Others
      Must Be Taking:Pembrolizumab

      170 Participants Needed

      Gene Therapy for Fabry Disease

      La Jolla, California
      This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Kidney Transplant, HIV, Diabetes, Others
      Must Be Taking:ERT

      18 Participants Needed

      DSP107 + Atezolizumab for Solid Tumors

      La Jolla, California
      Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors. Part 2: Preliminary efficacy assessment of DSP107 in combination with atezolizumab in second or third line treatment of non small cell lung cancer. Preliminary efficacy assessment of DSP107 as a single agent or in combination with atezolizumab in third line treatment of colorectal cancer.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Autoimmune Disease, Liver Disease, Others
      Must Not Be Taking:Immunosuppressants, Immunostimulants, Atezolizumab, Others

      125 Participants Needed

      1...678

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in San Diego, CA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in San Diego, CA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in San Diego, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in San Diego, CA is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in San Diego, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in San Diego, CA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in San Diego, CA?

      Most recently, we added LevoCept for Birth Control, Rebecsinib for Acute Myeloid Leukemia and Myelofibrosis and VRC07-523LS + PGT121.414.LS for HIV to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in California

      Anxiety Clinical Trials in California

      Schizophrenia Clinical Trials in California

      ADHD Clinical Trials in California

      Bipolar Disorder Clinical Trials in California

      Multiple Sclerosis Clinical Trials in California

      Autism Clinical Trials in California

      Treatment Resistant Depression Clinical Trials in California

      Borderline Personality Disorder Clinical Trials in California

      Social Anxiety Disorder Clinical Trials in California

      Parkinson's Disease Clinical Trials in California

      Alzheimer's Disease Clinical Trials in California

      By Location

      Clinical Trials near Los Angeles, CA

      Clinical Trials near San Francisco, CA

      Clinical Trials near San Diego, CA

      Clinical Trials near Sacramento, CA

      Clinical Trials near La Jolla, CA

      Clinical Trials near Orange, CA

      Clinical Trials near Stanford, CA

      Clinical Trials near Palo Alto, CA

      Clinical Trials near Long Beach, CA

      Clinical Trials near Duarte, CA

      Clinical Trials near Oakland, CA

      Clinical Trials near Torrance, CA

      Other People Viewed

      By Subject

      Top Clinical Trials near San Diego, CA

      Top Depression Clinical Trials near San Diego, CA

      Top Glioblastoma Clinical Trials near San Diego, CA

      Top Diabetes Clinical Trials near San Diego, CA

      Top Autism Clinical Trials near San Diego, CA

      Top Lung Cancer Clinical Trials near San Diego, CA

      Top Colorectal Cancer Clinical Trials near San Diego, CA

      Top Breast Cancer Clinical Trials near San Diego, CA

      Top Prostate Cancer Clinical Trials near San Diego, CA

      Top Fibromyalgia Clinical Trials near San Diego, CA

      Top Lymphedema Clinical Trials near San Diego, CA

      Top Schizophrenia Clinical Trials near San Diego, CA

      By Trial

      Levothyroxine for Heart Transplant Recipients

      Cytology Collection Methods for HPV Screening

      Omeprazole + Lifestyle Therapy for Laryngopharyngeal Reflux

      Mobile Health Intervention for Smoking

      CHW Support for Quitting Smoking During Pregnancy

      Online Program for Healthy Lifestyle

      Triple Therapy for Bladder Cancer

      Opioid-Dispensing Device for Postoperative Pain

      Olaparib for Acute Myeloid Leukemia with IDH Mutation

      Brain Monitoring and Stimulation Device for Epilepsy

      PrEP for Pre-Exposure Prophylaxis Uptake

      CLBR001 CAR-T for Non-Hodgkin's Lymphoma

      Related Searches

      Top Fibromyalgia Clinical Trials near San Diego, CA

      Top Clinical Trials near Tampa, FL

      Radiosurgery + Olaparib + Immunotherapy for Breast Cancer Brain Metastases

      TIL Therapy + Pembrolizumab for Skin Cancer

      GRC 54276 + Immunotherapy for Advanced Cancers

      LYT-100 for Idiopathic Pulmonary Fibrosis

      Delgocitinib Cream and Alitretinoin for Chronic Hand Dermatitis

      Tirzepatide vs Dulaglutide for Type 2 Diabetes

      Crizotinib for Cancer

      Prehabilitation Exercise for Ovarian Cancer

      Microwave Treatment for Actinic Keratosis

      SNS-101 + Cemiplimab for Cancer